CNS Pharmaceuticals, Inc. — 2023 Form 10-K Summary
Business context and reporting period
For the fiscal year ended December 31, 2023, CNS Pharmaceuticals was a clinical-stage company developing treatments for brain and central nervous system cancers. Its lead candidate, Berubicin, is being studied in recurrent glioblastoma; the company had no approved products and generated no product revenue.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $14.10 million | $9.30 million |
| General and administrative expense | $4.77 million | $5.97 million |
| Total operating expenses | $18.87 million | $15.27 million |
| Net loss | $18.85 million | $15.27 million |
| Net loss per share | $5.00 | $11.22 |
| Cash used in operating activities | $14.14 million | $10.56 million |
| Cash and cash equivalents, year-end | $548,721 | $10.06 million |
| Working capital | Deficit of approximately $4.54 million | Not stated in the MD&A excerpt |
| Current liabilities | $6.13 million | $4.92 million |
| Notes payable | $300,806 | $409,968 |
There is no meaningful operating margin to report because the company had no product revenue. Stockholders’ equity moved from $8.13 million at year-end 2022 to a deficit of $4.43 million at year-end 2023. Accumulated deficit reached $69.57 million.
Material changes versus 2022
- Net loss increased by approximately $3.58 million, primarily as research and development expense rose by $4.80 million with continued clinical-trial activity and related CRO and patient costs.
- General and administrative expense declined by approximately $1.20 million, mainly due to lower professional expenses, compensation, stock-based compensation, and insurance costs.
- Operating cash use increased by approximately $3.58 million. Year-end cash fell by approximately $9.51 million.
- Financing provided $4.64 million in 2023, compared with $15.61 million in 2022; 2023 financing included approximately $2.32 million from common-stock sales and $2.96 million from warrant exercises.
Outlook, risks, and unusual items
- Clinical program: Berubicin is in a randomized, controlled study versus lomustine, with 2:1 allocation and overall survival as the primary endpoint. In December 2023, an independent DSMB recommended continuing the study without modification after its interim futility review. Management remained blinded; the recommendation does not establish efficacy. The company expected final trial data in the first half of 2025, while noting timing depends on patient survival.
- Funding and going concern: The auditor highlighted substantial doubt about the company’s ability to continue as a going concern because of recurring losses and a net capital deficiency. Management estimated available cash and subsequent financing would fund operations into, but not beyond, the latter half of the second quarter of 2024. It estimated needing another $15–$17 million to complete the potentially pivotal Berubicin trial, plus working capital; further development of WP1244/WP1874 could require an additional $5 million. These estimates may change, and funding is not assured.
- Subsequent financing and dilution: An offering closed February 1, 2024, raising approximately $3.99 million gross before fees and expenses and including substantial warrants and pre-funded warrants. The filing reports that 2,204,667 pre-funded warrants had been exercised by April 1, 2024. This financing does not eliminate the stated funding risks.
- Nasdaq listing: The company did not meet Nasdaq’s minimum stockholders’ equity requirement by its February 2024 deadline and requested a hearing to contest delisting. Separately, Nasdaq notified the company in February 2024 of a bid-price deficiency, with an initial compliance period through August 26, 2024.
- Financial controls: Management found internal control over financial reporting ineffective at year-end due to insufficient segregation of duties, limited timely CRO cost information, and inadequate formal control documentation. Prior-period financial statements for 2021 and several 2022 quarters were corrected for previously unrecorded R&D expense and liabilities. Disclosure controls were also deemed ineffective.
- Other risks: The business depends heavily on Berubicin’s clinical success, future financing, third-party manufacturing and CRO performance. Licensed U.S. patents for Berubicin expired in March 2020; orphan-drug designation is described as the primary protection. The company also disclosed related-party licensing and sublicense arrangements involving its founder’s affiliates.
- Audit opinion: The auditor gave an unqualified opinion that the financial statements fairly present the company’s financial position and results under U.S. GAAP, while separately emphasizing substantial doubt about going concern.
Important facts for investors to verify
- Current cash runway, obligations and financing required to complete the Berubicin trial and fund operations.
- Trial enrollment and follow-up status, timing of final overall-survival results, and whether later data support efficacy and safety.
- Outcome of Nasdaq hearings and compliance with both stockholders’ equity and minimum-bid-price requirements.
- Progress in remediating material weaknesses and the accuracy and completeness of CRO-reported trial costs.
- Actual share count, warrant terms and potential dilution from the February 2024 financing and any further capital raises.
- Status of the UTMDACC WP1244 license, including the disclosed unmet commercial-diligence milestones and the institution’s termination rights.